Tom Loosli

Statistics

Publications

Citations

205

H-Index

Active since

2023

Affiliations

University Hospital of Zurich(Current)

University of Zurich

University of Bern

University of St.Gallen

University of Geneva

Tom Loosli is an author at University Hospital of Zurich specializing in antiretroviral therapy, drug resistance mutations, and resistance-associated mutations.

ORCID

Publications per year

2023–2025

Publications

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis

Tom Loosli, Stefanie Hossmann, Suzanne M Ingle et al. · The Lancet HIV · 2023 · 128 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +16

Predicted dolutegravir resistance in people living with HIV in South Africa during 2020–35: a modelling study

Tom Loosli, Nuri Han, Anthony Hauser et al. · The Lancet Global Health · 2025 · 24 citations · Full text

Public Health, Infectious Diseases, Pharmacology +17

Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1

Suraj Balakrishna, Tom Loosli, Maryam Zaheri et al. · Journal of Antimicrobial Chemotherapy · 2023 · 18 citations · Full text

Public Health, Molecular Medicine, Clinical Epidemiology +16

HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study

Caroline Lanz, J.H. Meier, Marcel Stoeckle et al. · Clinical Infectious Diseases · 2024 · 14 citations · Full text

Public Health, Biostatistics, Infectious Diseases +11

Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study

Tom Loosli, Carolyn Bolton‐Moore, Lydia Buzaalirwa et al. · Clinical Infectious Diseases · 2025 · 11 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17

1–5 of 6